-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Iq35O3WvG6EmuzD35lxhrhZq315QhfQlCCN7fPScZzotnaPIkgM2ZdLmQ2PM9fuR S2CFGzGktvysV7TI3ueyxg== 0000898822-04-000123.txt : 20040202 0000898822-04-000123.hdr.sgml : 20040202 20040202155503 ACCESSION NUMBER: 0000898822-04-000123 CONFORMED SUBMISSION TYPE: 425 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20040202 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: AVENTIS CENTRAL INDEX KEY: 0000807198 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 SEC ACT: 1934 Act SEC FILE NUMBER: 001-10378 FILM NUMBER: 04559290 BUSINESS ADDRESS: STREET 1: 67917 STRASBOURG STREET 2: CEDEX 9 CITY: STRASBOURG FRANCE STATE: I0 ZIP: 00000 BUSINESS PHONE: 3314768123 MAIL ADDRESS: STREET 1: 67917 STRASBOURG STREET 2: CEDEX 9 CITY: STRASBOURG FRANCE STATE: I0 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: RHONE POULENC S A DATE OF NAME CHANGE: 19930512 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: SANOFI SYNTHELABO SA CENTRAL INDEX KEY: 0001121404 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133529324 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 BUSINESS ADDRESS: STREET 1: 174 AVENUE DE FRANCE CITY: PARIS STATE: I0 ZIP: 75013 BUSINESS PHONE: 33153774400 MAIL ADDRESS: STREET 1: 174 AVENUE DE FRANCE CITY: PARIS STATE: I0 ZIP: 75013 425 1 feb2425.txt FORM 425 Filed by Sanofi-Synthelabo Pursuant to Rule 135 and Rule 425(b) under the United States Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14d-2(b)(2) of the United States Securities Exchange Act of 1934, as amended Subject Company: Aventis Commission File No. 001-10378 Date: February 2, 2004 ON FEBRUARY 2, 2004, THE FOLLOWING TWO ADVERTISEMENTS WERE PUBLISHED ON BEHALF OF SANOFI-SYNTHELABO IN THE FINANCIAL TIMES EUROPEAN EDITION AND THE INTERNATIONAL HERALD TRIBUNE EUROPEAN EDITION. * * * * WE REFUSE TO ACCEPT THAT SCIENTISTS DO NOT WORK TOGETHER TO SPEED UP THEIR RESEARCH. [Close-up image of old man leaning on walking stick] In an essential field such as healthcare, we must do everything possible to move faster. The coming together of Sanofi-Synthelabo and Aventis means thousands of scientists throughout the world working towards a common goal and combatting diseases more effectively. Our project will harness our complementary skills to create a leading pharmaceutical group (No.1 in Europe and No.3 worldwide) committed to improving healthcare and capable of driving strong, sustainable and profitable growth. SANOFI-SYNTHELABO'S OFFER TO AVENTIS'S SHAREHOLDERS BECAUSE HEALTH MATTERS This advertisement does not constitute an offer to sell, or an offer to purchase, any securities www.sanofi-synthelabo.com WE REFUSE TO ACCEPT THAT WE CANNOT DEVELOP MEDICINES FOR TOMORROW JUST BECAUSE OF OUR SIZE. [Image of young girl looking upward] Out of every 100,000 molecules screened only one becomes a new drug. Research is a major investment: it takes an average of 12 years and 800 million euros to obtain a medicine. That is why teaming up with Aventis will help us deliver more effective solutions to meet patients' needs. Together, we will harness our complementary skills to create a leading pharmaceutical group (No.1 in Europe and No.3 worldwide) committed to improving healthcare and capable of driving strong, sustainable and profitable growth. SANOFI-SYNTHELABO'S OFFER TO AVENTIS'S SHAREHOLDERS BECAUSE HEALTH MATTERS This advertisement does not constitute an offer to sell, or an offer to purchase, any securities www.sanofi-synthelabo.com -----END PRIVACY-ENHANCED MESSAGE-----